AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Intuitive Surgical Inc (NASDAQ:ISRG)
529.58 USD
+3.110 0.591%Sponsored Reports
Loading...
| Previous Close (in USD) | 526.47 |
|---|---|
| Change | +3.110 0.591% |
| 52 W H/L (in USD) | 408.430/254.850 |
| EBITDA (in USD) | 2267.4M |
| PE Ratio | 73.05 |
| Volume | 960843 |
| Diluted Eps TTM | 5.49 |
| Total Assets (in USD) | 15441.5M |
|---|---|
| Total Liabilities (in USD) | 2044.2M |
| Revenue TTM (in USD) | 7318.5M |
| Cash (in USD) | 2750.1M |
| Market Cap (in USD) | 142,247.739 M |
| Revenue Per Share TTM | 20.790 |
| Gross Profit TTM (in USD) | 4196M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Intuitive Surgical Inc
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
Employees: 13676
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Gary S. Guthart Ph.D. | Pres, CEO & Director | 1966 |
| 2. | Mr. Marshall L. Mohr | Exec. VP of Global Bus. Services | 1956 |
| 3. | Mr. David J. Rosa | Exec. VP and Chief Strategy & Growth Officer | 1968 |
| 4. | Dr. Myriam J. Curet McAdams F.A.C.S., M.D. | Exec. VP & Chief Medical Officer | 1957 |
| 5. | Mr. Robert DeSantis | Exec. VP & Chief Product Officer | 1966 |
| 6. | Mr. Jamie E. Samath | Sr. VP & CFO | 1971 |
| 7. | Mr. Fredrik Widman | VP, Principal Accounting Officer & Corp. Controller | NA |
| 8. | Mr. Philip Kim | Head of Investor Relations | NA |
| 9. | Mr. Gary Loeb | Gen. Counsel & Chief Compliance Officer | NA |
| 10. | Mr. Julian Nikolchev | Sr. VP of Corp. Devel. & Strategy | 1954 |
Peers
Sector: Healthcare
Industry: Medical Instruments & Supplies
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
ESLOY
Essilor International SA |
-0.640 0.532% | 120.15 | 35.390 | 24.814 | 3.630 | 2.204 | 3.996 | 16.255 |
|
ESLOF
EssilorLuxottica Société anonyme |
-3.500 1.437% | 240 | 35.710 | 25.126 | 3.623 | 2.229 | 3.995 | 16.251 |
|
BDX
Becton Dickinson and Company |
+1.060 0.473% | 223.33 | 37.720 | 15.924 | 3.252 | 2.490 | 4.085 | 17.104 |
|
ALC
Alcon AG |
+0.010 0.012% | 84.7 | 36.950 | 25.126 | 4.400 | 2.316 | 4.796 | 36.975 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | 1606.8M | 1890.3M | 1207M | 1502.2M | 1279.5M |
| Minority Interest | -22.1M | -23.5M | 6.2M | 2.5M | -2.9M |
| Net Income | 1322.3M | 1704.6M | 1060.6M | 1379.3M | 1127.9M |
| Selling General Administrative | 1739.9M | 1466.5M | 1216M | 1178.4M | 986.6M |
| Gross Profit | 4196M | 3958.5M | 2861.2M | 3110.2M | 2604.1M |
| Reconciled Depreciation | 365.8M | 310.2M | 276.2M | 203M | 122.8M |
| Ebit | 1211.3M | 1510.8M | 773.6M | 1171.5M | 1076.6M |
| Ebitda | 1577.1M | 1821M | 1049.8M | 1374.5M | 1199.4M |
| Depreciation And Amortization | 365.8M | 310.2M | 276.2M | 203M | 122.8M |
| Operating Income | 1211.3M | 1821M | 773.6M | 1374.5M | 1199.4M |
| Other Operating Expenses | 4645.1M | 3889.1M | 3308.6M | 3104M | 2524.8M |
| Interest Expense | 29.7M | 356M | 427.2M | 328.2M | 0M |
| Tax Provision | 262.4M | 162.2M | 140.2M | 120.4M | 154.5M |
| Interest Income | 29.7M | 69.3M | 157.2M | 127.7M | 80.1M |
| Net Interest Income | 29.7M | 69.3M | 157.2M | 127.7M | 80.1M |
| Income Tax Expense | 262.4M | 162.2M | 140.2M | 120.4M | 154.5M |
| Total Revenue | 6222.2M | 5710.1M | 4358.4M | 4478.5M | 3724.2M |
| Total Operating Expenses | 2618.9M | 2137.5M | 1811.4M | 1735.7M | 1404.7M |
| Cost Of Revenue | 2026.2M | 1751.6M | 1497.2M | 1368.3M | 1120.1M |
| Total Other Income Expense Net | 395.5M | 69.3M | 433.4M | 127.7M | 80.1M |
| Net Income From Continuing Ops | 1344.4M | 1728.1M | 1066.8M | 1381.8M | 1125M |
| Net Income Applicable To Common Shares | 1322.3M | 1704.6M | 1060.6M | 1379.3M | 1127.9M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 15441.5M | 12974M | 13555M | 11168.9M | 9733.2M |
| Intangible Assets | 636.7M | 49.8M | 70.5M | 77.4M | 112.1M |
| Other Current Assets | 176.7M | 164.3M | 271.1M | 267.5M | 200.2M |
| Total Liab | 2044.2M | 1861.4M | 1603.5M | 1409.8M | 1448.5M |
| Total Stockholder Equity | 13307.6M | 11112.6M | 11951.5M | 9759.1M | 8284.7M |
| Other Current Liab | 998.6M | 1276.1M | 1068.3M | 945.8M | 568.9M |
| Common Stock | 0.4M | 0.4M | 0.4M | 0.1M | 0.1M |
| Capital Stock | 0.4M | 0.4M | 0.4M | 0.1M | 0.1M |
| Retained Earnings | 4743M | 3500.1M | 4760.9M | 3261.3M | 2494.5M |
| Good Will | 348.7M | 348.5M | 343.6M | 336.7M | 307.2M |
| Other Assets | - | 1183.6M | 13555M | 2127M | 680.5M |
| Cash | 2750.1M | 1581.2M | 1290.9M | 1622.6M | 1167.6M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 1658.7M | 1861.4M | 1603.5M | 1409.8M | 1448.5M |
| Current Deferred Revenue | 446.1M | 438.3M | 414M | 382.4M | 365.2M |
| Net Debt | -2660.3M | -1581.2M | -1203.9M | -1622.6M | -1167.6M |
| Short Term Debt | 25.3M | - | - | - | -568.9M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 89.8M | - | 87M | - | - |
| Other Stockholder Equity | 8576.4M | 7774.6M | 7214.4M | 6472.8M | 5777.7M |
| Property Plant Equipment | - | 2374.2M | 1876.4M | 1577.3M | 1272.9M |
| Total Current Assets | 7888M | 8576.8M | 9989.3M | 8116.1M | 7511.5M |
| Long Term Investments | 2120M | 2623.6M | 4415.5M | 1757.7M | 2623.5M |
| Short Term Investments | 2473.1M | 2541M | 2940M | 3548.9M | 2054.1M |
| Net Receivables | 1267.5M | 942.1M | 782.7M | 645.5M | 645.2M |
| Long Term Debt | - | - | - | - | - |
| Inventory | 1220.6M | 893.2M | 587.1M | 601.5M | 595.5M |
| Accounts Payable | 188.7M | 147M | 121.2M | 81.6M | 1083.3M |
| Accumulated Other Comprehensive Income | -12.2M | -162.5M | -24.2M | 24.9M | 12.4M |
| Non Currrent Assets Other | 597.6M | -1613.7M | -3511.2M | -986.6M | -2407.5M |
| Non Current Assets Total | 7553.5M | 4397.2M | 3565.7M | 3052.8M | 2221.7M |
| Capital Lease Obligations | - | - | 87M | - | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Investments | 1258.9M | 1916M | -2099.3M | -561.4M | -669.1M |
| Total Cashflows From Investing Activities | - | 1370.8M | -2461.5M | -940.6M | -1154.4M |
| Total Cash From Financing Activities | -287.6M | -2572.3M | 43M | -85.7M | -168.4M |
| Net Income | 1817.3M | 1344.4M | 1728.1M | 1066.8M | 1381.8M |
| Change In Cash | 1169.4M | 294.7M | -332.5M | 455.9M | 273.2M |
| Begin Period Cash Flow | 1600.7M | 1306M | 1638.5M | 1182.6M | 909.4M |
| End Period Cash Flow | 2770.1M | 1600.7M | 1306M | 1638.5M | 1182.6M |
| Total Cash From Operating Activities | 1813.8M | 1490.8M | 2089.4M | 1484.8M | 1598.2M |
| Depreciation | 421.8M | 365.8M | 310.2M | 276.2M | 203M |
| Other Cashflows From Investing Activities | - | -12.8M | -8.7M | -37.7M | -59.7M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -712.5M | -546.6M | -256M | -170.1M | -360.5M |
| Sale Purchase Of Stock | -416.3M | -2607.4M | -211.6M | -134.3M | -269.5M |
| Other Cashflows From Financing Activities | -167.6M | -198.7M | -21.9M | -260.2M | -171.7M |
| Capital Expenditures | 1064.2M | 532.4M | 353.5M | 341.5M | 425.6M |
| Change In Working Capital | -777.6M | -619.1M | -368.1M | -273.2M | -321.5M |
| Other Non Cash Items | 40.3M | 71.8M | 32.6M | -38M | 7.1M |
| Free Cash Flow | 749.6M | 958.4M | 1735.9M | 1143.3M | 1172.6M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Performer (AFRIS) | 9 months ago | 64030583 |
| 2. | Vanguard Total Stock Mkt Idx Inv | 7 months ago | 11088810 |
| 3. | Vanguard Institutional 500 Index Trust | 7 months ago | 8963947 |
| 4. | Invesco QQQ Trust | 7 months ago | 6620686 |
| 5. | AF High Growth (AFRIS) | 9 months ago | 4866590 |
| 6. | Fidelity 500 Index | 8 months ago | 4258098 |
| 7. | SPDR® S&P 500 ETF Trust | 7 months ago | 4161408 |
| 8. | iShares Core S&P 500 ETF | 7 months ago | 3628426 |
| 9. | Vanguard Growth Index Investor | 7 months ago | 3379607 |
| 10. | American Funds Growth Fund of Amer A | 8 months ago | 2772682 |
| 11. | Capital Group Growth Fnd of Amer Comp | 8 months ago | 2772682 |
| 12. | Edgewood Growth Instl | 11 months ago | 2641820 |
| 13. | Health Care Select Sector SPDR® ETF | 7 months ago | 2568301 |
| 14. | T. Rowe Price US Lrg-Cap Core Gr Eq Comp | 8 months ago | 2317012 |
| 15. | T. Rowe Price Blue Chip Growth | 8 months ago | 2317012 |
| 16. | Capital Group New Perspective Comp | 8 months ago | 2316761 |
| 17. | American Funds New Perspective A | 8 months ago | 2316761 |
| 18. | Vanguard Institutional Index I | 7 months ago | 2303047 |
| 19. | Global Balanced (AFRIS) | 9 months ago | 2232522 |
| 20. | Capital Group Growth Composite | 8 months ago | 2058000 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | FMR Inc | 11 months ago | 7539646 |
| 2. | Jennison Associates LLC | 8 months ago | 4488343 |
| 3. | Edgewood Management LLC | 8 months ago | 4051849 |
| 4. | NORGES BANK | 11 months ago | 3892691 |
| 5. | Baillie Gifford & Co Limited. | 8 months ago | 3878506 |
| 6. | Amvescap Plc. | 11 months ago | 3494116 |
| 7. | Northern Trust Corp | 11 months ago | 3411221 |
| 8. | Nuveen Asset Management, LLC | 11 months ago | 3405120 |
| 9. | Vanguard Group Inc | 8 months ago | 30868620 |
| 10. | BlackRock Inc | 11 months ago | 29243893 |
| 11. | T. Rowe Price Associates, Inc. | 8 months ago | 16530249 |
| 12. | State Street Corporation | 11 months ago | 14960837 |
| 13. | Capital World Investors | 8 months ago | 7284269 |
| 14. | Geode Capital Management, LLC | 11 months ago | 6938605 |
| 15. | Bank of New York Mellon Corp | 11 months ago | 6706824 |
| 16. | AllianceBernstein L.P. | 8 months ago | 6603732 |
| 17. | Goldman Sachs Group Inc | 11 months ago | 5241682 |
| 18. | JPMorgan Chase & Co | 11 months ago | 5210598 |
| 19. | Morgan Stanley - Brokerage Accounts | 11 months ago | 5147165 |
| 20. | Fisher Asset Management, LLC | 8 months ago | 4571023 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Related Articles
Loading...
